HMO expansion: Jennewein Biotechnologie to strengthen portfolio with Arthus Mineralsprings facility buy
09 0ct 2018 --- Jennewein Biotechnologie is to expand its production of human milk oligosaccharides (HMO) from its current portfolio of two products to include five more. The expansion is facilitated through the company's acquisition of the former facilities of Arthus Mineralsprings in Bad Hönningen, Germany. Jennewein plans to build a new integrated fermentation and recovery plant for the production of HMOs. “With the new plant, we will be able to produce additional HMOs, expanding our current portfolio of two products (2′ fucosyllactose and lacto-N-neotetraose) to include five more (3′ fucosyllactose, difucosyllactose, lacto-N-tetraose, 6′-sialyllactose and 3′-sialyllactose),” says Benedikt Engels, Chief Operation Officer at Jennewein. “We have been searching for some time for a suitable location to establish an integrated HMO fermentation and recovery plant close to our current facility in Rheinbreitbach,” says Dr. Stefan Jennewein, CEO and Co-Founder of the company.  Click to Enlarge
portfolio from two to five ingredients. HMOs form the third most abundant solid component of human milk after lactose and fat and research increasingly demonstrates that much of breast milk's value lies within these components. HMOs have prebiotic properties and are incredibly complex to replicate, but are increasingly sought after in infant nutrition products. Jennewein will continue to focus on the infant and medical nutrition markets, but a spokesperson for the company tells NutritionInsight that the option for developing products in the adult nutrition area may be a future possibility too. The new integrated facility will combine fermentation and recovery, and will yield spray-dried HMO products. Jennewein Biotechnologie plans to build separate production lines for the manufacture of each of the new HMO products. “The new plant will become one of the largest fermentation facilities in central Europe,” adds Stephan Michel, Chief Financial Officer. Jennewein Biotechnologie is an international industrial biotechnology company with a range of products in the field of complex oligosaccharides (HMOs) and rare monosaccharides. In 2015, the US Food and Drug Administration (FDA) granted a license to market 2′-fucosyllactose in the US. This was followed in 2017 by European Union marketing authorization under the Novel Food Regulation. To contact our editorial team please email us at editorial@cnsmedia.com
Related ArticlesHealth & Nutrition News Weekly Roundup: Two Aker Biomarine krill patents deemed unpatentable in US court, no single diet can eliminate belly fat24 Aug 2018 --- The weekly roundup is NutritionInsight's collection of global nutrition stories from the past week. No single diet can specifically eliminate belly fat research has found, but certain healthful traits can reduce or prevent abdominal obesity. Sabinsa has added two new US staff members and NP Nutra has expanded its warehouse space in California. The European Commission has authorized microalgae oil, Schizochytrium, for novel food status and the US patent authorities have found that patents related to krill and its production held by Aker Biomarine are unpatentable, following petitions from Rimfrost AS. While, DSM has made Fortune Magazine’s 2018 Change the World list for the third consecutive year. Health & Nutrition News “Industry first”: DSM plans first dedicated early life nutrition premix plant22 Aug 2018 --- Royal DSM is planning to open what it claims is the industry’s only premix manufacturing facility built exclusively for the maternal and infant nutrition market. Construction of the state-of-the-art plant is due to start in the next few weeks and financial details are not being disclosed. Located in Buk, Poland, the company expects the investment to double production output at the site within the next two years. Health & Nutrition News GOS holds dietary fiber potential: FrieslandCampina eyes new applications13 Aug 2018 --- FrieslandCampina is targeting the dietary fiber opportunity for its Galacto-Oligosaccharides (GOS). The move comes in response to the recent FDA green light on specific dietary fibers which presents new market opportunities and application areas. “There is a lot of interest in clean, green and label-friendly ingredients and fiber is one that they are looking for, but in good tasting applications. This really means a lot more flexibility for formulators to offer something that has both prebiotic and fiber benefits,” Sarah Staley of FrieslandCampina tells NutritionInsight on the topic of GOS as a trending prebiotic fiber. Health & Nutrition News Whey basic protein isolate safe for use in infant nutrition, EFSA rules01 Aug 2018 --- Whey basic protein isolate is safe for use in infant and follow‐on formula and meal replacement beverages, dietary foods for special medical purposes and as food supplements, the European Food Safety Authority (EFSA) has concluded. The application for EFSA’s scientific opinion was submitted by French dairy ingedients company Armor Protéines. Health & Nutrition News Infant nutrition collaboration: BASF and UC Davis to tap into gut-brain axis26 Jul 2018 --- Further benefits of Human Milk Oligosaccharides (HMO) for infant formula hoped to be unlocked through a new BASF and the University of California Davis (UC Davis) collaboration. The long-term objective of the strategic partnership is to tap into the gut-brain axis by developing and validating second-generation HMO molecules as potent bioactive compounds. More Articles |
